Imbalance between alpha-1-antitrypsin and interleukin 6 is associated with in-hospital mortality and thrombosis during COVID-19Short communication Published on 2022-08-012022-10-05 Journal: Biochimie [Category] 바이오마커, 치료기술, [키워드] 95%CI adjusted Admission age alpha-1-antitrypsin Anti-inflammatory Anticoagulant BMI COVID-19 COVID-19 severity Critically ill cross-sectional D-dimer levels examined hallmark Hospitalization hospitalized patient IL-6 Imbalance in-hospital mortality Inflammation intensity involved Logistic regression marker mechanism Mortality multivariable analysis non-survivor Occurrence offer pathophysiology Patient patients performed phenotyped plasma predict Predictive proportion Protective protective factor Restoring severe COVID-19 severity Sex subset suffered survivor therapeutic thrombosis tissue variant with COVID-19 [DOI] 10.1016/j.biochi.2022.07.012 [Article Type] Short communication
Prognostic Value of Mid-Region Proadrenomedullin and In Vitro Interferon Gamma Production for In-Hospital Mortality in Patients with COVID-19 Pneumonia and Respiratory Failure: An Observational Prospective StudyCOVID-19 폐렴 및 호흡부전 환자의 병원 내 사망률에 대한 중간 지역 Proadrenomedullin 및 체외 인터페론 감마 생산의 예후적 가치: 관찰적 전향적 연구Observational Study Published on 2022-07-302022-09-11 Journal: Viruses [Category] MERS, 바이오마커, 임상, [키워드] 95%CI Admission Adult patients adverse outcome adverse outcomes AUROC best Biomarker cause characterized Coagulopathy Comorbidity coronavirus coronavirus disease COVID-19 COVID-19 pneumonia COVID-19 vaccination cut-off cut-off point Deceased dysregulation endothelial damage enrolled Enrollment Evidence evidence of females Gamma groups Hospital mortality Hospitalization IFNγ immune dysregulation Immune suppression Immunocompromised patients in vitro in-hospital mortality infection risk interferon interferon gamma median age mid-region proadrenomedullin MONITOR Mortality MR-proADM Negative predictive value Non-COVID-19 observational study PaO2:FiO2 Patient patients with COVID-19 Pneumonia predict Predictive value predictive value) Production Prognostic factor Prospective quantiferon monitor. radiologic respiratory Respiratory failure SARS-CoV-2 sensitivity significantly specificity subset survivor the median value were measured with COVID-19 with infection [DOI] 10.3390/v14081683 PMC 바로가기 [Article Type] Observational Study
The effect of reparixin on survival in patients at high risk for in-hospital mortality: a meta-analysis of randomized trials병원 내 사망 위험이 높은 환자의 생존에 대한 레파릭신의 효과: 무작위 시험의 메타 분석Meta-Analysis Published on 2022-07-252022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 임상, [키워드] 95% confidence interval addition all-cause mortality antagonist anti-inflammatory drug Anti-inflammatory drugs article CENTRAL Chemokine receptor comparator control group Controlled controlled trials COVID-19 Critical Critical care CXCL-8 CXCL8 CXCR1 CXCR2 CXCR2 antagonist heterogeneity high risk identify IL-8 In-hospital in-hospital mortality include independent Infection inhibitor Intensive intensive & involved Meta-analysis no difference Odds ratio P -value Patient patients performed Pneumonia Randomized controlled trial Randomized controlled trials randomized trial randomized trials RCT RCTs receptor receptors Reparixin risk of bia risk of infection RoB 2 SARS-CoV-2 SARS-COV-2 infection screened searched Sepsis shown significantly lower suggested survival Treatment trials two groups was used [DOI] 10.3389/fimmu.2022.932251 PMC 바로가기 [Article Type] Meta-Analysis
The usefulness of D-dimer as a predictive marker for mortality in patients with COVID-19 hospitalized during the first wave in Italy이탈리아의 첫 번째 물결 동안 입원한 COVID-19 환자의 사망률에 대한 예측 마커로서 D-dimer의 유용성Article Published on 2022-07-222022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 바이오마커, [키워드] addition age Analysis assist C-index Clinical characteristics co-morbidity cohort study competing coronavirus disease Coronavirus disease 2019 COVID-19 cumulative cumulative incidence D-dimer death diagnosed with COVID-19 died dimer First wave global health Health healthcare hospital Hospital mortality Hospitalized hospitalized patient hospitalized patients identification in-hospital mortality incidence Italy lead lombardy majority marker medical staff Model moderate morbidities Mortality occurred outcome Patient patient records patients patients with COVID-19 performed Predictive Predictive value predictor primary endpoint Real-time PCR resources risk Sex statistical analyses study population survival Treatment was obtained [DOI] 10.1371/journal.pone.0264106 PMC 바로가기 [Article Type] Article
Safety and efficacy of mesenchymal stem cells in severe/critical patients with COVID-19: A systematic review and meta-analysisArticle Published on 2022-07-092022-10-06 Journal: EClinicalMedicine [Category] 진단, [키워드] 95% CI adverse event AEs applied benefit cellular therapy China Chinese CNKI Cochrane Library control group Coronavirus disease-19 (COVID-19) COVID-19 Critical database Descriptive analysis development disease category dose doses Efficacy Efficacy and safety Egger Free heterogeneity in-hospital mortality in-hospital mortality rate Innovation less Mesenchymal stem cells Meta-analysis mortality rate MSC MSCs optics original Patient patients with COVID-19 Placebo plan Primary outcome Program reduce mortality Safe Safety Science searched Secondary outcomes significant difference small sample size standard care standard treatment stem cell stromal cell subgroup analysis Support systematic review technology the disease Tianjin Trade Treatment Trial two groups Valley was performed were used Wuhan [DOI] 10.1016/j.eclinm.2022.101545 PMC 바로가기 [Article Type] Article
Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis코로나19로 입원한 환자에서 토실리주맙, 사릴루맙, 28일 후 모든 원인 사망률 사이의 연관성: 네트워크 메타 분석Meta-Analysis Published on 2022-07-082022-09-11 Journal: PLoS ONE [Category] meta-analysis, 임상, 진단, [키워드] 28-day mortality all-cause mortality antagonist association choice clinician Consistency Corticosteroid Corticosteroids COVID-19 patient deaths demonstrated dependent on Effect eligible patient Evidence hospitalised patient Hospitalised patients in-hospital mortality inconsistency initiated interleukin-6 interleukin-6 receptor invasive ventilation Meta-analysis Network meta-analysis Non-invasive not dependent Odds ratio Odds ratios P-value Patient Placebo randomisation randomised randomised comparison receiving receptor antagonist REMAP-CAP REMAP-CAP trial sarilumab Tocilizumab Trial usual care Ventilation with COVID-19 [DOI] 10.1371/journal.pone.0270668 PMC 바로가기 [Article Type] Meta-Analysis
Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trialRandomized Controlled Trial Published on 2022-07-012022-10-05 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 임상, [키워드] Adverse adverse event adverse events Antiviral Antiviral agents clinical Combination combination regimen combination therapy COVID-19 Day demonstrated Efficacy Efficacy and safety event examined Favipiravir FVP group groups hospital ICU admission ill patient in-hospital mortality incidence interferon Interferon-beta IQR LOS median Mild not different not significantly different Patient Potential treatment primary endpoint randomization Randomized randomized clinical trial Randomly receive Registered registry SARS-coronavirus SARS-CoV-2 Seven single-center Treatment treatment regimen Trial viral clearance [DOI] 10.1002/jmv.27724 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety of ACEi and ARB in COVID-19 management: A retrospective analysisObservational Study Published on 2022-07-012022-10-05 Journal: Clinical Cardiology [Category] COVID19(2023년), SARS, 임상, [키워드] ACEi ACEi/ARB acute respiratory syndrome Affect Analysis angiotensin receptor blocker Angiotensin-converting enzyme ARB ARBs association clinical guideline complex interplay confounding variable congestive heart failure contagious coronavirus coronavirus disease COVID-19 COVID-19 patient COVID-19 patients enrolled Evidence Factor hospital Host hypertension in-hospital mortality increased mortality individual Inflammatory response Interaction material medication Mortality multicenter multiorgan failure pathway Patient patient data patients Primary outcome regression analysis retrospective Retrospective analysis Safety SARS-CoV2 SARS-CoV2 infection severe COVID-19 severity severity of COVID-19 Society SQL USA variable virus was done were used [DOI] 10.1002/clc.23836 PMC 바로가기 [Article Type] Observational Study
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers ColloquiumCOVID-19의 혈전 위험에 대한 현재 및 신규 바이오마커: 국제 COVID-19 혈전증 바이오마커 콜로키움의 합의 성명Review Published on 2022-07-012022-09-11 Journal: Nature reviews. Cardiology [Category] COVID19(2023년), MERS, SARS, 바이오마커, 임상, 치료기술, 치료법, [키워드] Activation aggregation Biomarker Biomarkers Clinical use Coagulation Coagulopathy Consensus coronavirus disease Coronavirus disease 2019 COVID-19 current D-dimer disease disease severity Elevation elevations Endothelial cell excessive inflammation fibrinogen fibrinolysis hypercoagulability in-hospital mortality Injury Intervention marker pandemic Patient patients Platelet platelet activation platelet aggregation platform Post-vaccine predict Prognosis prothrombotic recommendation Research risk risk stratification syndrome thrombocytopenia thromboembolic Thromboembolic events thrombosis thrombotic thrombotic and thromboembolic events thrombotic risk with COVID-19 [DOI] 10.1038/s41569-021-00665-7 PMC 바로가기 [Article Type] Review
Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID studyObservational Study Published on 2022-07-012022-10-04 Journal: Intensive care medicine [Category] 임상, [키워드] Administered administration affected age Analysis assessment Bacterial baseline benefit Care clinically Corticosteroid corticosteroid treatment Corticosteroids covariate COVID-19 COVID-19 patient Critically ill Critically ill patient Dexamethasone dosage dose doses of corticosteroid early administration Evidence failure higher risk hospitalisation ICU ICU admission ICUs Illness severity in-hospital mortality increased risk Inflammation information intensive care interaction term Invasive mechanical ventilation investigated Laboratory lower risk Major mechanical ventilation Modification Mortality multivariable analysis no effect nosocomial Observational cohort study organ damage Patient patients with COVID-19 performed personalised Pneumonia potential benefit Primary outcome Protective receiving severe coronavirus disease severity Significant SOFA Spanish steroid subgroup subgroups subgroups of patient symptom onset systemic corticosteroid Treatment use of corticosteroid variable with COVID-19 [DOI] 10.1007/s00134-022-06726-w PMC 바로가기 [Article Type] Observational Study